{
  "asset": {
    "name": "KT-579",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "target": "IRF5",
    "mechanism": "First-in-class oral IRF5 degrader",
    "modality": "Oral small molecule degrader",
    "partner": null
  },
  "clinical_development": {
    "current_stage": "Phase 1 (planned)",
    "indications_in_development": [
      "Lupus",
      "Sj\u00f6gren's",
      "RA",
      "IBD",
      "SSc",
      "DM"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [
    {
      "event": "Phase 1 HV trial start",
      "timing": "Q1 2026"
    },
    {
      "event": "Phase 1 HV data",
      "timing": "2H 2026"
    }
  ],
  "_source_pages": [
    11,
    37,
    41
  ],
  "_last_extracted": "2026-02-04T13:13:42.035375"
}